Capula Management’s Edwards Lifesciences EW Stock Holding History

Capula Management’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$56.1K	Buy	+700	New	+$57.7K	﹤0.01%	982
2021 Q2	–	Sell	-21,300	Closed	-$1.78M	–	803
2021 Q1	$1.78M	Sell	21,300 -96,300	-82%	-$8.14M	0.04%	302
2020 Q4	$10.7M	Buy	+117,600	New	+$9.75M	0.53%	45
2019 Q4	–	Sell	-4,200	Closed	-$308K	–	395
2019 Q3	$308K	Buy	+4,200	New	+$295K	0.01%	285

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Capula Management's EW Position: Q1 2026 in Review

Capula Management opened a new position in Edwards Lifesciences (EW) in Q1 2026: 460 shares worth $36.8K. The stake represents ﹤0.01% of the portfolio and ranks #1017 among its holdings. This is a return to the name: Capula Management previously reported a position in EW as recently as Q4 2022.

Capula Management first reported a position in EW in Q2 2021 and has held it in 5 quarters since. The position peaked at $964K in Q4 2022. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

Capula Management held 460 shares of Edwards Lifesciences worth $36.8K as of Q1 2026.
Edwards Lifesciences was a new Capula Management position in Q1 2026.
Edwards Lifesciences made up ﹤0.01% of Capula Management's portfolio in Q1 2026, its #1017 holding.
Capula Management first reported a position in Edwards Lifesciences in Q2 2021 and has held it in 5 quarters since.
Capula Management's Edwards Lifesciences position peaked at $964K in Q4 2022.
1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Capula Management's 13F filing for Q1 2026, filed 14 May 2026.